the second completed phase ii clinical trial for opicinumab, called synergy by biogen, concluded in march 2016 but failed to reach its primary endpoint, which was an integrated measure of several ms progression and disability markers: ambulation, extremity functionality, cognition, and other typical indicators of ms. results from the study also showed highly unanticipated dose-response relationships in the ms patient population that will likely require further clinical trials to investigate satisfactorily.